CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes

NCT ID: NCT07140848

Last Updated: 2025-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-02

Study Completion Date

2028-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prediabetes affects over one-third of adults in the United States, placing them at a higher risk for developing type 2 diabetes and heart disease, which can lead to serious health complications and increased medical costs. Although a program called the Diabetes Prevention Program (DPP) has been shown to lower the risk of diabetes through healthy lifestyle changes, many people find it difficult to stick with these changes over the long term. This study seeks to find out if combining DPP coaching with continuous glucose monitoring (CGM) technology can help people stay on track with their health goals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CGM devices give individuals real-time information about their blood sugar levels, which can help them understand how their diet, exercise, and daily habits impact their health. By pairing CGM technology with support from trained DPP coaches, this approach aims to make it easier for participants to maintain healthy behaviors. The study will involve 214 adults with prediabetes who will follow a 12-month program with regular check-ins to measure improvements in blood sugar control, weight loss, physical activity, and overall quality of life.

The goal is to show whether using CGM in combination with coaching can lead to better health outcomes and whether it is a cost-effective way to prevent diabetes. If successful, this approach could be used in healthcare settings across the country, helping more people prevent diabetes and lead healthier lives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PreDiabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Diabetes Prevention Program

Group Type ACTIVE_COMPARATOR

Control

Intervention Type BEHAVIORAL

Participants in control group will be referred to DPP.

Intervention

Diabetes Prevention Program + Continuous Glucose Monitors/Coaching

Group Type EXPERIMENTAL

CGM-DPP

Intervention Type BEHAVIORAL

Participants in the DPP who receive personalized CGM coaching.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGM-DPP

Participants in the DPP who receive personalized CGM coaching.

Intervention Type BEHAVIORAL

Control

Participants in control group will be referred to DPP.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. adults aged 18 years or older,
2. diagnosis of prediabetes, as defined by current clinical guidelines (HbA1c 5.7% to 6.4%, fasting plasma glucose 100-125 mg/dL, or 2-hour plasma glucose 140-199 mg/dL following a 75g oral glucose tolerance test),
3. body mass index (BMI) of at least 24 kg/m² (or 22 kg/m² for Asian Americans),
4. willingness to comply with all aspects of the study protocol, including attending coaching sessions and using CGM devices.

Exclusion Criteria

Individuals will be excluded from the study if they

1. have a diagnosis of type 1 or type 2 diabetes,
2. are currently using CGMs or have medical contraindications to CGM use, such as severe skin allergies or implantable defibrillators, or
3. are currently enrolled in another clinical trial for prediabetes. Additionally, using validated assessments, we will exclude participants with significant dementia, alcohol or drug abuse/dependency, active psychosis, or life expectancy less than 12 months as these conditions are likely to interfere with adherence to the intervention.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

State University of New York at Buffalo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raphael Fraser, PhD

Associate Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raphael A Fraser, PhD, MS

Role: CONTACT

7168295733

Jocelyn Stooks, MPH

Role: CONTACT

7168292364

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADA Grant #7-25-ICTSPC-412

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

STUDY00009767

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.